// App-Quantinova.ai

: Indacaterol/glycopyrronium increases lung ventilation in COPD patients as measured by hyperpolarized 3He MRI

Researchers

Presenter

  • Hanns-Christian Tillmann

Principal Investigators

  • David Singh

  • Dinesh Saralaya

  • Rod Lawson

  • Jim Wild

  • Jonathan Goldin

  • Konstantinos Kostikas

  • Kristin Smith

  • Surendra Machineni

  • Denise Yates

Medical Centers

  • Novartis Institutes for BioMedical Research, Basel, Switzerland

  • Medicines Evaluation Unit, Manchester, United Kingdom.

  • Rheumatology, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom

  • Sheffield Teaching Hospital NHS Foundation Trust and Sheffield University, Sheffield, United Kingdom

  • University of Sheffield, Sheffield, United Kingdom

  • University of California Los Angeles - Los Angeles - United States of America

  • Novartis AG, Basel, Switzerland

  • Novartis Institute for Biomedical Research, Cambridge, MA, United States

  • Novartis Healthcare Pvt. Ltd, Hyderabad, India

Locations

  • Switzerland

  • United Kingdom

  • United States

  • India

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • Seebri Breezhaler

  • indacaterol

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Cross Over

  • Double Blind/Blinded

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved